Age and Sex Differences in Efficacy of Treatments for Type 2 Diabetes

医学 内科学 2型糖尿病 临床试验 胰高血糖素样肽1受体 糖尿病 二肽基肽酶-4 安慰剂 不利影响 梅德林 内分泌学 受体 兴奋剂 替代医学 病理 政治学 法学
作者
Peter Hanlon,Elaine Butterly,Lili Wei,Heather Wightman,Saleh Ali Almazam,Khalid Alsallumi,Jamie Crowther,Ryan McChrystal,Heidi Rennison,Katherine Hughes,Jim Lewsey,Robert S. Lindsay,Stuart J. McGurnaghan,John L. Petrie,Laurie A. Tomlinson,Sarah H. Wild,Amanda Adler,Naveed Sattar,David Phillippo,Sofia Dias
出处
期刊:JAMA [American Medical Association]
卷期号:333 (12): 1062-1062 被引量:42
标识
DOI:10.1001/jama.2024.27402
摘要

Importance: Sodium-glucose cotransporter 2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, and dipeptidyl peptidase 4 (DPP4) inhibitors improve hyperglycemia, and SGLT2 inhibitors and GLP-1 receptor agonists reduce the risk of major adverse cardiovascular events (MACEs) among individuals with type 2 diabetes. It is not clear whether efficacy varies by age or sex. Objective: To assess whether age or sex are associated with differences in the efficacy of SGLT2 inhibitors, GLP-1 receptor agonists, and DPP4 inhibitors. Data Sources and Study Selection: The MEDLINE and Embase databases and US and Chinese clinical trial registries were searched for articles published from inception to November 2022; in August 2024, the search was updated to capture the trial results. Two reviewers screened for randomized clinical trials of SGLT2 inhibitors, GLP-1 receptor agonists, or DPP4 inhibitors vs a placebo or active comparator in adults with type 2 diabetes. Data Extraction and Synthesis: Individual participant data and aggregate data were used to estimate age × treatment interactions and sex × treatment interactions in multilevel network meta-regression models. Main Outcome and Measures: Hemoglobin A1c (HbA1c) and MACEs. Results: Of the 601 eligible trials identified (592 trials with 309 503 participants reported HbA1c; mean age, 58.9 [SD, 10.8] years; 42.3% were female and 23 trials with 168 489 participants reported MACEs; mean age, 64.0 [SD, 8.6] years; 35.3% were female), individual participant data were obtained for 103 trials (103 reported HbA1c and 6 reported MACEs). The use of SGLT2 inhibitors (vs placebo) was associated with less HbA1c lowering with increasing age for monotherapy (absolute reduction [AR], 0.24% [95% credible interval {CrI}, 0.10% to 0.38%] per 30-year increment in age), for dual therapy (AR, 0.17% [95% CrI, 0.10% to 0.24%]), and for triple therapy (AR, 0.25% [95% CrI, 0.20% to 0.30%]). The use of GLP-1 receptor agonists was associated with greater HbA1c lowering with increasing age for monotherapy (AR, -0.18% [95% CrI, -0.31% to -0.05%] per 30-year increment in age) and for dual therapy (AR, -0.24% [95% CrI, -0.40% to -0.07%]), but not for triple therapy (AR, 0.04% [95% CrI, -0.02% to 0.11%]). The use of DPP4 inhibitors was associated with slightly better HbA1c lowering in older people for dual therapy (AR, -0.09% [95% CrI, -0.15% to -0.03%] per 30-year increment in age), but not for monotherapy (AR, -0.08% [95% CrI, -0.18% to 0.01%]) or triple therapy (AR, -0.01% [95% CrI, -0.06% to 0.05%]). The relative reduction in MACEs with use of SGLT2 inhibitors was greater in older vs younger participants per 30-year increment in age (hazard ratio, 0.76 [95% CrI, 0.62 to 0.93]), and the relative reduction in MACEs with use of GLP-1 receptor agonists was less in older vs younger participants (hazard ratio, 1.47 [95% CrI, 1.07 to 2.02]). There was no consistent evidence for sex × treatment interactions with use of SGLT2 inhibitors and GLP-1 receptor agonists. Conclusions and Relevance: The SGLT2 inhibitors and GLP-1 receptor agonists were associated with lower risk of MACEs. Analysis of age × treatment interactions suggested that SGLT2 inhibitors were more cardioprotective in older than in younger people despite smaller reductions in HbA1c; GLP-1 receptor agonists were more cardioprotective in younger people.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
谨岛嗦完成签到 ,获得积分10
刚刚
完美世界的应助被科研通管家采纳,获得10
刚刚
xiaoming777完成签到,获得积分10
刚刚
刚刚
刚刚
跳跃以山的应助被科研通管家采纳,获得10
刚刚
上官若男的应助被科研通管家采纳,获得10
刚刚
李健的应助被科研通管家采纳,获得10
刚刚
慕青的应助被科研通管家采纳,获得10
刚刚
HMONEY完成签到,获得积分10
刚刚
桐桐的应助被科研通管家采纳,获得30
刚刚
爆米花的应助被科研通管家采纳,获得10
1秒前
ding的应助被科研通管家采纳,获得10
1秒前
嘻嘻哈哈的应助被科研通管家采纳,获得10
1秒前
Lucas的应助被科研通管家采纳,获得10
1秒前
乐乐笑语的应助被科研通管家采纳,获得10
1秒前
CAOHOU的应助被科研通管家采纳,获得10
1秒前
2秒前
2秒前
2秒前
2秒前
2秒前
breeze完成签到,获得积分10
2秒前
gaos发布了新的文献求助10
3秒前
DW的应助被rafayel采纳,获得10
3秒前
左安完成签到,获得积分10
4秒前
长安发布了新的文献求助20
4秒前
4秒前
不安的飞珍完成签到,获得积分10
4秒前
4秒前
5秒前
王乐乐发布了新的文献求助30
6秒前
6秒前
不灭钻石完成签到,获得积分10
7秒前
ty完成签到,获得积分10
7秒前
甜美砖家发布了新的文献求助10
8秒前
LKF完成签到,获得积分10
8秒前
hpc发布了新的文献求助10
9秒前
巫马尔槐发布了新的文献求助10
9秒前
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Agyptische Geschichte der 21.30. Dynastie 510
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8191868
求助须知:如何正确求助?哪些是违规求助? 9578583
关于积分的说明 21860514
捐赠科研通 7791338
什么是DOI,文献DOI怎么找? 3436743
关于科研通互助平台的介绍 2560477
邀请新用户注册赠送积分活动 2483527